| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
HGF improves pathological conditions during ischemic organ diseases through inducing anti-apoptotic and regenerative properties. There is now emerging evidence to show that over-activation of “innate immune system” by HMGB1 triggers excessive inflammatory events and accelerates organ dysfunction. Using a mouse model of renal ischemia, we demonstrated that HGF-mediated anti-apoptotic outcomes in parenchaymal cells leads to the suppression of extra-cellular HMGB1 secretion. Furthermore, we found that HGF directly targeted macrophages to intercept HMGB1-TLR4 signaling transduction, followed by the repression in NF-κB activations. Overall, we delineated the new functions of HGF, such as (i) inhibition of HMGB1-primed activation of TLR4 downstream (i.e., receptor side) and (ii) suppression of HMGB1 secretion from dying cells (i.e., ligand side) as well. Such a dual property of HGF likely contributes to the improvement in ischemic organ disorders.
|
